VYGR

1.5304.97%
KB

Krystof Bankiewicz

Founder

Dr. Krystof Bankiewicz M.D., Ph.D. is an Advisor of MRI Interventions, Inc. He serves as Member of Scientific Advisory Board at AviadoBio Ltd. Dr. Bankiewicz is Founder of Voyager Therapeutics, Inc. He serves as Scientific Chair, Parkinson’s and MSA at Asklepios BioPharmaceutical, Inc. He is a leader in AAV gene therapy and has brought multiple AAV therapies to the clinic. He has both industry and academic experience. He has considerable experience in supervising multi-investigator translational programs and is a principal investigator on several multi-center, multi-investigator grants and clinical trials. His main area of expertise focuses on in vivo models of Parkinson's disease, neuroimaging, the dopaminergic system and convection-enhanced delivery of viral vectors in the brain. Dr. Bankiewicz serves as a Member of Ced Advisory Committee MedGenesis Therapeutix Inc. and served as its Member of the Scientific Advisory Board. He also serves as a Member of Advisory Board of Oxford Biomedica Plc and SanBio Inc. He served as a Member of CNS Scientific Advisory Board at uniQure N.V. (formerly, uniQure BV). He is the Kinetics Foundation Chair in Translational Research and Professor in Residence of Neurological Surgery and Neurology at the University of California at San Francisco (UCSF). Dr. Bankiewicz is also Vice Chair for Research in the Department of Neurosurgery and Director of Interventional Neurology Center at UCSF. He has created a world class laboratory at the University of California, San Francisco, focusing on the delivery of therapeutic agents into the central nervous system through automated cell-implantation, convection-enhanced and gene transfer-based delivery methods, as well as in vivo applications of MRI and PET to detect in-vivo changes in brain and their correlation with functional outcome. He is an inventor on numerous patents and has published more than 180 peer-reviewed research articles. He has supervised a total of 35 postdoctoral fellows and manages a core research group of 20 people, including technicians, postdoctoral fellows and senior scientists. Throughout his career, Dr. Bankiewicz has maintained a strong focus on the development of translational approaches to gene and cell replacement therapies and he has displayed the ability to synthesize distinct technologies into powerful new approaches to the treatment of serious diseases, including brain cancer, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, pediatric neurotransmitter deficiency and lysosomal storage disorders. Dr. Bankiewicz holds several patents, including those for use of neuro-derived fetal cell lines for transplantation therapy, convection-enhanced delivery of adeno-associated virus (AAV) vectors and CED of AAV viral vector with AADC for the treatment of Parkinson's disease. He is internationally recognized for his work on gene and cell delivery into the central nervous system. Dr. Bankiewicz was a recipient of Fogarty Fellowship and trained at the National Institutes of Neurological Disorders and Stroke at NIH, Bethesda, Md. Dr. Bankiewicz holds an M.D. from Jagiellonian University in Crakow and a Ph.D., D.Sc., from the Institute of Neurology and Psychiatry in Warsaw, Poland and Professor title by the President of Republic of Poland.

Positions